Shortness of breath at rest, chest pain, fainting, or sudden swelling of the legs with breathlessness need emergency care (call 911).
The number is never read on its own. It shifts with age, kidney function and body weight, and it is interpreted next to your history, a physical examination, an ECG and usually an echocardiogram. This article is educational and not medical advice.
It measures the concentration of B-type natriuretic peptide circulating in the blood, which rises roughly in step with how much the walls of the heart's chambers are being stretched. Muscle cells in the ventricles, mainly the left ventricle, respond to pressure or volume load by making a precursor protein. That precursor is cut into two pieces, the active hormone BNP and an inactive fragment called NT-proBNP, which enter the circulation in equal numbers of molecules 1.
Because both pieces come from the same precursor, a lab can measure either one and learn something similar about cardiac wall stress. Most labs run one assay or the other, and the two numbers are not interchangeable.
Two features of the marker are worth holding onto. The trigger is mechanical, so the hormone answers the question of how stretched this heart is at the moment of the draw, not what the underlying diagnosis is. And the signal is dynamic, able to climb within hours as filling pressures rise and to settle again as those pressures come down.
That combination makes it a sensitive signal of cardiac loading and a poor one for pinpointing a cause. A result is the start of an assessment, not the end of one.
The heart releases natriuretic peptides to reduce its own workload, acting as a counterweight to the systems that make the body hold on to salt and water. Once in the circulation these peptides promote the excretion of sodium and water by the kidneys, relax blood vessels and oppose the hormonal cascade that drives fluid retention and vasoconstriction, which together lower the pressure and the volume the heart has to move 2.
So the hormone is a distress signal with a built-in response attached. A healthy heart at rest produces little of it. When a ventricle faces sustained pressure overload, for example from long standing high blood pressure or a narrowed valve, or sustained volume overload, production climbs and stays elevated while the load persists.
This is also why the marker tracks severity reasonably well. The more stretch, the more hormone released, which is why values often run higher in people who are more symptomatic and fall as congestion eases.
In everyday clinical work, both BNP and the inactive NT-proBNP fragment are used as readouts of this loading state rather than as tests for a single disease 3.
They come from the same precursor, but BNP is the active hormone and NT-proBNP is the leftover inactive fragment, and that difference changes how each behaves in blood and how each is handled in the lab 3.
| Feature | BNP | NT-proBNP |
|---|---|---|
| What it is | The biologically active hormone | The inactive fragment of the precursor |
| Time in circulation | Shorter, cleared quickly | Longer, so reported values run higher |
| Main routes of clearance | Receptor binding and enzyme breakdown, with some renal clearance | Largely passive, with the kidneys doing more of the work |
| Sample handling | More particular about collection tube and stability after the draw | More stable, measurable in serum or plasma |
| What it is used for | Assessment of suspected heart failure and of cardiac loading | Assessment of suspected heart failure and of cardiac loading |
| Comparing values | Not interchangeable with NT-proBNP | Not interchangeable with BNP |
Two practical points follow. First, a BNP figure and an NT-proBNP figure cannot be compared directly, so a report should always say which was measured. Second, assays from different manufacturers do not produce identical numbers, which is why practical guidance from the Heart Failure Association stresses that the test used and the setting both shape how a concentration should be interpreted 4.
If you are tracking a value over time, the most useful comparison is the same test, run by the same lab, measured under similar circumstances.
The main use is to help work out how likely heart failure is in someone who has symptoms such as breathlessness, fatigue or swollen ankles, and to decide who should have imaging next. Consensus algorithms from the Heart Failure Association place a natriuretic peptide measurement early in the assessment of suspected heart failure, and measuring it may help a clinician decide who should go on to an echocardiogram 5.
A second use is to gauge risk. Research suggests that, in people with heart failure with preserved ejection fraction, higher BNP and NT-proBNP concentrations predict a higher risk of adverse outcomes 6.
A third use is follow-up. Because concentrations respond to changes in filling pressure, a series of values can add information about whether congestion is improving or building, which is why practical guidance addresses serial measurement as well as single readings 4.
It is just as important to be clear about what the test does not do. It does not name a cause, it does not reliably separate one type of heart failure from another, and guidance frames it as part of a diagnostic pathway in people with symptoms rather than as a general screening test for people without any 4. A result is read with the history, the examination and the imaging, never alone.
Because the marker is sensitive but not specific. Untreated heart failure almost always raises natriuretic peptides, so a value under the usual rule-out level makes the diagnosis unlikely, while raised values appear in many other situations that load or stress the heart, which is why guidance presents the low thresholds as rule-out levels rather than diagnostic cut-offs 4.
Put plainly, a low number is a strong negative and a high number is a prompt to look further. That asymmetry is useful. In a clinic full of people who are short of breath for many different reasons, a quick blood test that confidently moves heart failure down the list saves time, worry and unnecessary imaging.
A value above the rule-out level does not identify heart failure on its own. It says the heart is under load, or that something else is lifting the concentration, and the next step is an assessment that looks for the reason, typically including an echocardiogram when the clinical picture supports it 5.
There is one more wrinkle. The rule-out logic is strongest when the person genuinely has symptoms, because the test was studied in that setting. Running it in someone with no symptoms produces numbers that are much harder to act on.
Typical lab reporting uses low cut points below which heart failure is considered unlikely, and these differ depending on whether symptoms came on gradually or suddenly. The values below are the commonly used rule-out levels described in Heart Failure Association guidance 4.
| Test | Typical rule-out level, symptoms developing gradually | Typical rule-out level, sudden or acute symptoms |
|---|---|---|
| BNP | below 35 pg/mL | below 100 pg/mL |
| NT-proBNP | below 125 pg/mL | below 300 pg/mL |
These are typical lab reference thresholds, not FitScript optimal ranges, and they vary by lab, assay, age and sex. Units are usually reported as pg/mL or ng/L, and the two are numerically the same.
In the acute setting, higher age-stratified NT-proBNP levels are also used to increase the likelihood of heart failure, commonly above 450 pg/mL under age 50, above 900 pg/mL between 50 and 75, and above 1800 pg/mL over 75 5.
A value above a rule-out level is an observation, not a diagnosis. It may reflect cardiac loading, reduced clearance or another condition entirely, and it is worth discussing with a clinician so the rest of the picture can be put around it.
Plenty, which is exactly why a high value is a question rather than an answer. Natriuretic peptide concentrations can be lifted by atrial fibrillation, older age, reduced kidney function, valve disease, thickening of the heart muscle, pulmonary embolism and pulmonary hypertension, acute coronary events, critical illness such as sepsis, anaemia and an overactive thyroid, all of which are recognised pitfalls when a plasma BNP value is interpreted 7.
Atrial fibrillation deserves a special mention because it is common and can raise values substantially on its own, which can make a result look like congestion when the rhythm is doing most of the work.
The logic to apply is the same each time. The observation is a concentration above the rule-out level. The meaning is that the heart is loaded, or that clearance is reduced, or that another condition is raising the number. The next step belongs to a clinician, who will look at the rhythm, kidney function, oxygen levels, the examination findings and usually cardiac imaging before drawing any conclusion.
None of this makes a raised value unimportant. Across many conditions, natriuretic peptides behave as markers of cardiac strain and of risk, which is part of why they have become routine in cardiology 2. A value outside the usual range should never be set aside, and a markedly raised value with new symptoms is worth discussing with a clinician promptly.
Because several things push concentrations down, and the most common one is body size. Research suggests that, in people with heart failure who carry more body fat, BNP concentrations run lower than in leaner people with comparable disease 8. A value that looks mid-range in someone with a high body mass index may still deserve a closer look.
Timing matters too. In sudden onset pulmonary congestion, a sample drawn very early can be taken before the concentration has fully risen. In people whose congestion has already been managed and who are stable, values may have fallen well below where they sat when they were unwell. Heart failure with preserved ejection fraction can also run with lower concentrations than the equivalent degree of symptoms would suggest, and conditions that restrict filling without stretching the ventricle wall may not raise the hormone as expected. These are among the recognised reasons a plasma value can mislead in either direction 7.
The practical conclusion is simple. A normal result in someone with convincing symptoms does not close the case. Guidance treats natriuretic peptides as one input into an algorithm that also weighs symptoms, signs, risk factors and the ECG 5. If you still feel unwell, say so, whatever the number says.
Age raises the baseline, and that is the single biggest reason a one-size cut-off does not work. Studies indicate that natriuretic peptide concentrations climb with age, which is why age-stratified thresholds are used to support a diagnosis of heart failure in the acute setting rather than a single number for everyone 5.
Part of the reason is that the heart and blood vessels stiffen with the years, so filling pressures tend to be a little higher at the same workload. Part of it is that kidney clearance tends to decline with age, which slows removal of the peptides from the circulation.
Sex also shifts the distribution. Women tend to have somewhat higher natriuretic peptide concentrations than men of the same age, something laboratories and guidance take into account when reference intervals are set.
What this means for you is straightforward. A number that would be unremarkable in a 75 year old can be notable in a 40 year old, and the same figure can read differently for a man and a woman. The comparison that counts is against an age-appropriate and sex-appropriate expectation, interpreted by a clinician who can see the rest of your results. That is also why comparing your figure with someone else's, or with a number found online, tells you very little.
They move it in opposite directions, and both effects are large enough to change how a result reads. The kidneys contribute to clearing natriuretic peptides from the blood, and the inactive NT-proBNP fragment depends on that clearance more heavily than the active hormone does 1. When filtration falls, concentrations rise even when the heart's loading has not changed, which is one of the best known pitfalls in interpreting these markers 7.
Body weight pushes the other way. A higher body mass index is associated with lower circulating BNP in people with heart failure, so adiposity can mask a value that would otherwise stand out 8.
Stack the two together and you can see the problem with reading a single figure in isolation. A heavier person with normal kidneys may test lower than their heart's loading would suggest. A slim older person with reduced filtration may test higher than their heart alone would explain.
This is the main argument for testing kidney function at the same time rather than afterwards. Practical guidance on using natriuretic peptide concentrations addresses exactly these modifying factors when a result is interpreted 4. Bring your weight, your age and your kidney numbers to the conversation, and the result becomes far easier to place.
Creatinine is a waste product cleared by the kidneys, and it is measured alongside cardiac markers because kidney function changes how a natriuretic peptide result should be read. The Creatinine guide covers what the marker is, how it is tested and what a result means.
In brief, FitScript's optimal range for creatinine, an optimization target rather than a diagnostic cut-off, is 0.8 to 1.2 mg/dL in men and 0.6 to 0.9 mg/dL in women, set against typical lab reference ranges of 0.6 to 1.3 mg/dL in men and 0.57 to 1 mg/dL in women. Typical reference ranges vary by lab, age and sex, and muscle mass influences creatinine independently of kidney function.
A creatinine result outside the usual range is worth discussing with a clinician, and it is one reason two people with the same cardiac marker figure can be told two different things.
It is a standard venous blood draw from the arm, usually taking a couple of minutes, with no fasting normally required. The sample goes to a laboratory analyser, and many hospitals can return a result within the hour because the test is often used while someone is still being assessed.
A few practical details matter more than patients expect. The collection tube and sample handling differ between the two markers, since the active hormone is the more particular of the pair, so a lab will specify which tube it needs. Point-of-care versions exist and are used where a fast answer changes the immediate plan.
Timing is worth thinking about. Because concentrations respond to filling pressures, a sample taken during symptoms carries different information from one taken on a settled day. Posture, recent intense exercise and recent intravenous fluids can all nudge a reading, so it helps to note the circumstances of the draw.
Finally, keep continuity. Different assays do not generate identical numbers, which is why guidance underlines that the assay and the clinical setting both shape interpretation, and why repeat testing is most informative when it uses the same method 4. Ask which marker was measured and note the units, so your next result can be compared with this one.
A trend often says more than a single figure, because each person has their own baseline. Someone with long standing heart disease may sit above a rule-out level all the time, so the informative question is whether today's value is higher, lower or roughly where it usually sits.
The prognostic signal supports this way of looking at it. A systematic review of people with heart failure with preserved ejection fraction found that higher BNP and NT-proBNP concentrations were associated with a higher risk of adverse outcomes, which makes the direction of travel clinically meaningful rather than cosmetic 6.
Two cautions apply. Natriuretic peptide concentrations vary from day to day within the same person, so a small shift may be noise rather than news, and practical guidance covers how serial values should be used and interpreted rather than treated as a scoreboard 4. And a change only means something if the same test and lab produced both numbers.
The useful habit is to keep your results in one place, with dates, units and the name of the marker, and to bring that history to your clinician. A rising trend alongside new breathlessness, weight gain over a few days or increasing ankle swelling is worth discussing with a clinician promptly, rather than waiting for the next scheduled appointment.
The ones that explain or modify the result, plus the ones that describe cardiovascular risk more broadly. Kidney markers come first, because filtration changes the concentration directly, so creatinine with an estimated filtration rate and electrolytes belong in the same draw. A full blood count matters because anaemia raises cardiac workload, thyroid function matters because an overactive thyroid can lift natriuretic peptides, and these are among the conditions recognised as confounders when a value is interpreted 7.
Alongside those, the markers that describe longer term cardiovascular risk give context that a single cardiac stress signal cannot. Lipids, including LDL cholesterol and apolipoprotein B, markers of glucose handling such as HbA1c, and an inflammatory marker such as high sensitivity CRP fill in the background against which any cardiac finding is read.
None of this replaces the clinical assessment. Diagnostic algorithms put the blood result next to symptoms, signs, the ECG and echocardiography, in that order of escalation 5.
A broad panel makes this easier to assemble in one sitting. FitScript tests 150+ biomarkers per year, Atlas, its AI health advisor, interprets the results in context, and a licensed provider evaluates whether any treatment is appropriate.
Any result outside the reference range on this test deserves a conversation, and some symptoms deserve one immediately. Breathlessness at rest or when lying flat, chest pain, fainting, a racing or irregular heartbeat with light-headedness, or sudden leg swelling with breathlessness are emergencies and need urgent care rather than a scheduled appointment.
Short of that, book a prompt review if you notice breathlessness on exertion that is new or getting worse, waking at night short of breath, swelling in the ankles that builds over days, rapid weight gain over a short period, or unusual fatigue with reduced exercise tolerance. A markedly raised value, or a value that has climbed since your last test, is worth discussing with a clinician promptly even if you feel reasonably well.
Bring the practical details with you. Which marker was measured, the units, the date, your weight, your kidney results and any new symptoms since the draw. That shortens the path to a useful answer.
Discuss your results and any proposed treatment with a clinician or licensed provider, who evaluates what is appropriate for you. Never set aside an abnormal result, and never stop or start anything on the basis of a number you read on a page.
For related reading, the heart health panel page sets out which cardiovascular markers are measured together in one draw, and the LDL cholesterol guide explains how that marker is reported and what influences it.
It helps a clinician judge how likely heart failure is in someone with symptoms such as breathlessness, fatigue or swollen ankles. The hormone rises when the heart's walls are stretched, so the result reflects how loaded the heart is at that moment. It is used to decide who needs imaging next, not to make a diagnosis on its own.
Fasting is not normally required for this test, and it is a routine blood draw from a vein in the arm. If it is being drawn as part of a wider panel that includes glucose or lipids, the lab may ask you to fast for those markers instead. Follow the instructions your clinic or lab gives you.
Both come from the same precursor molecule in heart muscle cells. BNP is the active hormone and NT-proBNP is the inactive fragment left behind, and NT-proBNP stays in the blood longer, so its reported numbers run higher. The two cannot be compared directly, so always check which one your report lists.
No. A raised value shows the heart is under load or that the peptides are being cleared more slowly, and several conditions can produce that picture. A clinician reads it with your symptoms, your examination, an ECG and usually an echocardiogram before reaching any conclusion. A high result is a reason to look further, not a diagnosis.
A value below the usual rule-out level makes heart failure much less likely, which is the test's main strength. It is not absolute, though, because body weight, timing of the draw and certain forms of heart disease can keep the number lower than expected. If you still have symptoms, tell your clinician regardless of the number.
The kidneys help clear these peptides from the blood, so reduced kidney function tends to raise the number even when the heart's loading has not changed. Higher body weight tends to lower it. That is why creatinine and an estimated filtration rate are usually measured at the same time.
That depends on why it was ordered and what the first result showed, and your clinician decides the interval. When a value is tracked over time, the comparison is most useful if the same test is run by the same lab each time. Keep your results with their dates and units so the trend can be seen.
You can ask, but it is designed to be used in people who have symptoms, which is where its results are easiest to interpret. In someone with no symptoms, a borderline figure often creates more questions than answers. Discuss with a clinician whether it adds anything useful for your situation.